ライフサイエンスコーパス: hematopoietic disorder

1 ntial role in EpoR-JAK2 V617F mutant-induced hematopoietic disorder.

2 at STAT5 is critical for JAK2 mutant-induced hematopoietic disorder.

3 tion program that result in various types of hematopoietic disorders.

4 us for blood cell formation in patients with hematopoietic disorders.

5 ansmitted among cats and causes a variety of hematopoietic disorders.

6 g the molecular aspects of hematopoiesis and hematopoietic disorders.

7 oietic system as well as for gene therapy of hematopoietic disorders.

8 as a target of gene transfer for therapy of hematopoietic disorders.

9 understanding and ameliorating skeletal and hematopoietic disorders.

10 lodysplastic syndromes (MDSs) are a group of hematopoietic disorders affecting the myeloid lineage, c

11 in this study would be therapeutic for many hematopoietic disorders and are supportive of a clinical

12 rative therapy for many benign and malignant hematopoietic disorders and as a platform for gene thera

13 and when inappropriately activated can cause hematopoietic disorders and oncogenesis.

14 to the molecular biology of several cancers, hematopoietic disorders, and diabetes.

15 apeutic strategies targeting klotho to treat hematopoietic disorders associated with aging.

16 Transfusion medicine and treatments of hematopoietic disorders associated with severe thrombocy

17 normal female genomic DNAs, and in 12 clonal hematopoietic disorder cDNAs, confirming assay validity.

18 Cyclic neutropenia (CN) is a congenital hematopoietic disorder characterized by remarkably regul

19 king interleukin-2 (IL-2) developed a severe hematopoietic disorder characterized by the abnormal dev

20 Erdheim-Chester disease (ECD) is a clonal hematopoietic disorder characterized by the accumulation

21 gerhans cell histiocytosis (LCH) is a clonal hematopoietic disorder defined by tumorous lesions conta

22 Histiocytoses are clonal hematopoietic disorders frequently driven by mutations m

23 These included genes in familial hematopoietic disorders (GATA2, RUNX1), telomeropathies

24 or therapeutic intervention in metabolic and hematopoietic disorders has been hampered by the relativ

25 signaling regulation is involved in various hematopoietic disorders; however, the detailed mechanism

26 Acute myeloid leukemia (AML) is a hematopoietic disorder initiated by the leukemogenic tra

27 o retrovirus-mediated gene therapy for human hematopoietic disorders is the low efficiency of gene tr

28 is a promising strategy to treat congenital hematopoietic disorders, levels of engraftment have not

29 erapy is a promising method for treatment of hematopoietic disorders, neurodegenerative diseases, dia

30 monocytic leukemia (JMML) is a unique clonal hematopoietic disorder of early childhood.

31 ytic leukemia (JMML) is a unique, aggressive hematopoietic disorder of infancy/early childhood caused

32 o 78.8 kg with acquired or congenital lympho-hematopoietic disorders or metabolic disease.

33 stacles for effective human gene therapy for hematopoietic disorders remains the achievement of an ad

34 regulated tyrosine kinase selectively causes hematopoietic disorders resembling human leukemias in an

35 l hemoglobinuria (PNH) is an acquired clonal hematopoietic disorder that occurs on a background of bo

36 This review focuses on hematopoietic disorders that are associated with mutatio

37 Myelodysplastic syndromes (MDS) are clonal hematopoietic disorders that are more common in patients

38 gly viewed as a disease spectrum, comprising hematopoietic disorders that extend across a phenotypic

39 Myeloid malignancies, a group of hematopoietic disorders that includes acute myeloid leuk

40 al variants are known to cause rare blood or hematopoietic disorders, the genome-wide contribution of

41 ncBAF, in multiple cancers, including clonal hematopoietic disorders, we evaluate here the role of BR

42 l hemoglobinuria (PNH) is an acquired clonal hematopoietic disorder with increased mortality and morb

43 Myelodysplastic syndrome (MDS) is a group of hematopoietic disorders with limited treatment options.